Joel Cohen
Corporate Officer/Principal at McGill University
Profile
Joel Cohen is currently a Principal at McGill University.
Previously, he was a Principal at various firms including Æterna Zentaris, Inc., 9342-8530 Québec, Inc., Fennec Pharmaceuticals, Inc., BELLUS Health, Inc., MP Biomedicals Canada ULC, Canaccord Genuity Group, Inc., and Bioniche, Inc. He holds an MBA from McGill University.
Joel Cohen active positions
| Companies | Position | Start |
|---|---|---|
| McGill University | Corporate Officer/Principal | - |
Former positions of Joel Cohen
| Companies | Position | End |
|---|---|---|
MP Biomedicals Canada ULC
 MP Biomedicals Canada ULC Miscellaneous Commercial ServicesCommercial Services MP Bio medicals Canada Ulc provides genomics and gene delivery research tools and services. The firm’s products include PCR, transfection, protemics, lab tools and instruments, and enzyme products. It has operations in Canada, France, Switzerland and the United States. The company was founded in 1991 and is headquartered in Montréal, Canada. | Corporate Officer/Principal | - |
| AETERNA ZENTARIS INC. | Corporate Officer/Principal | - |
| 9342-8530 QUÉBEC INC. | Corporate Officer/Principal | - |
| Bioniche, Inc. | Corporate Officer/Principal | - |
| FENNEC PHARMACEUTICALS INC. | Corporate Officer/Principal | - |
Training of Joel Cohen
| McGill University | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 4 |
|---|---|
| CANACCORD GENUITY GROUP INC. | Finance |
| FENNEC PHARMACEUTICALS INC. | Health Technology |
| 9342-8530 QUÉBEC INC. | Health Technology |
| AETERNA ZENTARIS INC. | Health Technology |
| Private companies | 3 |
|---|---|
BELLUS Health, Inc.
 BELLUS Health, Inc. Pharmaceuticals: MajorHealth Technology BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada. | Health Technology |
| Bioniche, Inc. | Health Technology |
MP Biomedicals Canada ULC
MP Biomedicals Canada ULC Miscellaneous Commercial ServicesCommercial Services MP Bio medicals Canada Ulc provides genomics and gene delivery research tools and services. The firm’s products include PCR, transfection, protemics, lab tools and instruments, and enzyme products. It has operations in Canada, France, Switzerland and the United States. The company was founded in 1991 and is headquartered in Montréal, Canada. | Commercial Services |
- Stock Market
- Insiders
- Joel Cohen
